{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:48:25Z","timestamp":1794350905017,"version":"4.9.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.annonc.2021.04.008","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:00:15Z","timestamp":1619092815000},"page":"881-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":378,"title":["Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189"],"prefix":"10.1016","volume":"32","author":[{"given":"D.","family":"Rodr\u00edguez-Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.G.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Pietanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.04.008_bib1","series-title":"KEYTRUDA\u00ae (Pembrolizumab). Full Prescribing Information","year":"2020"},{"key":"10.1016\/j.annonc.2021.04.008_bib4","series-title":"Australian Product Information\u2014KEYTRUDA\u00ae (Pembrolizumab). Summary of Product Characteristics","year":"2020"},{"issue":"11","key":"10.1016\/j.annonc.2021.04.008_bib5","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2021.04.008_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.annonc.2021.04.008_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.04.008_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2021.04.008_bib10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.04.008_bib11","doi-asserted-by":"crossref","unstructured":"Barlesi F, Nishio M, Cobo M. et\u00a0al. IMpower132: efficacy of atezolizumab (atezo) 1 carboplatin (carbo)\/cisplatin (cis) 1 pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Paper presented at the European Society for Medical Oncology. October 19-23, 2018; Munich, Germany.","DOI":"10.1093\/annonc\/mdy424.066"},{"issue":"21","key":"10.1016\/j.annonc.2021.04.008_bib12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.04.008_bib13","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Ciuleanu TE, Yu X, et\u00a0al. Nivolumab (nivo)\u00a0+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small-cell lung cancer (aNSCLC): CheckMate 227 part 2 final analysis. Paper presented at the ESMO-Immuno Oncology. December 11-14, 2019; Geneva, Switzerland.","DOI":"10.1093\/annonc\/mdz453.004"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.008_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.04.008_bib15","doi-asserted-by":"crossref","unstructured":"Socinski MA, Mok TSK, Nishio M et\u00a0al. IMpower150 final analysis: efficacy of atezolizumab (atezo)\u00a0+ bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. Paper presented at the American Association for Cancer Research Annual Meeting. April 27-28, 2020; Virtual Meeting I.","DOI":"10.1158\/1538-7445.AM2020-CT216"},{"issue":"21","key":"10.1016\/j.annonc.2021.04.008_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.annonc.2021.04.008_bib17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.annonc.2021.04.008_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.008_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.21037\/tlcr-19-396","article-title":"Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2021.04.008_bib20","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10183","key":"10.1016\/j.annonc.2021.04.008_bib21","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:03:22Z","timestamp":1760335402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421011467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0923753421011467"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.04.008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}